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Mutations of the type III receptor tyrosine kinase (RTK) FLT3 occur in 
approximately 30% of acute myeloid leukemia (AML) patients and lead to constitutive 
activation.  This has made FLT3 activating mutations an attractive drug target, as they are 
probable driver mutations of this disease.  As more potent FLT3 inhibitors are developed, 
a predictable development of resistance-conferring point mutations, commonly at residue 
D835, has been observed.  Crenolanib is a highly selective and potent FLT3 tyrosine 
kinase inhibitor (TKI) with activity against the internal tandem duplication (FLT3/ITD) 
mutants as well as against the FLT3/D835 point mutants.  We tested crenolanib against a 
panel of D835 mutant cell lines and primary patient blasts and observed superior 
cytotoxic effects when compared to other available FLT3 TKIs such as quizartinib and 
sorafenib.  Another potential advantage of crenolanib is its reduced inhibition of c-Kit 
compared to quizartinib.  In progenitor cell assays, crenolanib was less disruptive of 
erythroid colony growth, which may result in relatively less myelosuppression than 
quizartinib.  Finally, correlative data from an ongoing clinical trial demonstrate that AML 
patients can achieve sufficient levels of crenolanib to inhibit both FLT3/ITD and 
resistance-conferring FLT3/D835 mutants in vivo.  Crenolanib is thus an important next-
generation FLT3 TKI.   
Several small molecule tyrosine kinase inhibitors (TKIs) used to treat hematologic 
malignancies have off target effects against c-Kit, a receptor tyrosine kinase required for 
normal hematopoiesis.  In animal models, abnormal c-Kit signaling results in impaired 
erythroid and megakaryocyte production.  AML patients taking FLT3 inhibitors with 




between c-Kit inhibition and myelosuppression, a panel of FLT3, c-Kit, and dual 
inhibitors were investigated.  The activity of each drug was determined against FLT3 and 
c-Kit and on hematopoietic colony formation.  Potent c-Kit inhibitors such as dasatinib, 
pazopanib, and quizartinib demonstrated the greatest disruption of erythroid colony 
formation.  Sorafenib, which has negligible activity against c-Kit, demonstrated minimal 
disruption of normal colony formation.  Our data highlights the importance of 
determining a therapeutic index between the targeted receptor and c-KIT for TKIs used to 
treat hematologic malignancies in order to maintain normal hematopoiesis and improve 
overall treatment outcomes. 
 
Mark Levis, M.D., Ph.D. (Thesis Advisor) 
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 FLT3 mutated AML 
Approximately one quarter of AML patients harbor an internal tandem duplication (ITD) 
in the receptor tyrosine kinase (RTK) FLT3 (Figure 1).
1
  Point mutations of FLT3 at aspartate 
835 (D835) are also observed in patients, although at a frequency of only about 7%.  The 
FLT3/ITD mutations are known to confer a poor prognosis, while the prognostic impact of the 
D835 mutations is more controversial.
1-3
  Both types of mutations lead to constitutive activation 
of the tyrosine kinase function, which makes FLT3 an attractive drug target to improve outcomes 
for AML patients with FLT3 mutations.   
Clinical efficacy of tyrosine kinase inhibitors against FLT3 point mutants in AML 
Over the past decade, several TKIs targeting FLT3 have been studied in the setting of 
clinical trials to treat AML with limited success.
4
  More recently, sorafenib and quizartinib have 
emerged as more potent FLT3 inhibitors and have significant clinical activity.
5-8
  Quizartinib in 
particular has been associated with high bone marrow response rates in relapsed and refractory 
FLT3/ITD AML patients, although there appeared to be a degree of myelosuppression in some 
patients, possibly the result of concomitant inhibition of c-KIT.
8,9
 
The BCR-ABL inhibitor imatinib has been in widespread use for CML and Ph+ ALL for 
a decade now.  Soon after its introduction into this patient population, resistance-conferring point 
mutations in the ABL kinase domain emerged during therapy, leading to disease progression.  
This has been successfully countered with the introduction of second-generation BCR-ABL 
inhibitors such as nilotinib and dasatinib.  In contrast, as clinical trials of FLT3 inhibitors were 
being conducted over the past decade, resistance-conferring point mutations in the FLT3 coding 
sequence were not routinely observed, except sporadically.
10
  A reasonable explanation for this is 
that high-level FLT3 inhibition in vivo was not generally achieved by the first generation FLT3 




widely used to treat FLT3/ITD AML, both in clinical trials and in off-label use, point mutations 
have finally emerged during disease progression.
11
  These mutations are predominantly found at 
aspartate 835 (D835) in the activation loop, although mutations at phenylalanine 691 (F691) were 
also reported.  Both mutations render the receptor resistant to the FLT3 inhibitor to a variable 
degree and are clearly associated with disease progression.  Resistance-conferring FLT3 D835 
mutations have also been reported to arise during sorafenib and sunitinib therapy.
12,13
  As the 
clinical development of FLT3 inhibitors proceeds into advanced phase trials, it has become 
obvious that these mutations will represent a new obstacle in the care of FLT3/ITD AML 
patients, at least when quizartinib or sorafenib are used as the initial TKI.  Furthermore, 
FLT3/D835 mutations present at diagnosis in 7% of AML patients and in some cases may 
represent a driver of the disease.
14-16
  While first generation FLT3 inhibitors such as midostaurin 
have activity against FLT3 tyrosine kinase domain mutations,
17,18
 their relative lack of potency 
has limited their utility as single agents. 
Crenolanib is a benzimadine quinolone derivative originally developed as an inhibitor of 
platelet-derived growth factor receptor (PDGFR).
19
  In a phase 1 trial of crenolanib enrolling solid 
tumor patients, eight patients achieved stable disease but no objective responses were reported, 
despite micromolar plasma concentrations being achieved in tolerable fashion.
19
  Subsequent 
analysis using an in vitro kinase assay indicated that the compound had activity against FLT3.   
We report here the characterization of crenolanib as a novel TKI that has potent activity against 
both the FLT3/ITD-mutated receptor as well as to FLT3/D835-mutated receptors, including those 
arising in the context of FLT3/ITD mutations following treatment with sorafenib and quizartinib. 
Mechanisms of resistance to tyrosine kinase inhibitors in AML 
There are many additional mechanisms of resistance to TKIs in AML beyond acquired 
mutations in the FLT3 receptor itself.  First, this constantly growing collection of FLT3 TKIs 




metabolized by CYP3A4 enzymes and therefore their pharmacokinetics are altered by 
concomitant administration of other CYP3A4-metabolized medications.  Variable degrees of 
plasma protein binding can greatly affect the efficacy of these drugs.
20
  Patients, especially those 
receiving chemotherapy, can have widely different concentrations of plasma FL which has also 
been demonstrated to decrease efficacy of FLT3 TKIs. 21   It has also been shown that these blasts 
will overcome their addiction to FLT3 signaling by activating parallel pathways including 
upregulation of various survival, proliferation, and anti-apoptotic molecules.
22
  AML is also a 
clonal disease, with various subpopulations constantly evolving in response to treatment.  The 
complexity of these issues has made it difficult to combat this issue of TKI resistance in AML. 
A particularly interesting and complex form of resistance is the contribution of the tumor 
microenvironment.  The bone marrow niche is well documented as a protective 
environment for both normal hematopoietic cells and malignant cells.  AML therapy is 
complicated by this stromal protection as it only takes only a small amount of residual 
leukemia stem cells surviving after the treatment to result in disease relapse.  We have 
demonstrated with a primary human bone marrow and primary human leukemia blast co-
culture system that bone marrow stroma confers on leukemia cells a protective effect 
against FLT3 TKIs.  The exact mechanism of this phenomenon is not yet clear but there 
are a few important details recently discovered.  TKIs are capable of inducing apoptosis 
in peripheral blasts but induce a pathway of differentiation rather than death in blasts on 
stroma.
23
 It has also been shown that stimulation of the MAPK pathway contributes to 
enhanced viability of blasts on stroma.
24
  Finally, the addition of FL is known to reduce 
the efficacy of TKIs in cell suspension.
21
  We hypothesized that stromal surface FL is 
playing a role in resistance and anti-FL mAbs may alleviate this stromal cell-mediated 




c-Kit and myelosuppression 
Myelosuppression is a common adverse event noted during the development of new 
agents for patients with leukemia.  Distinguishing between disease-related effects and the effects 
of the therapy can be a challenge. Tyrosine kinase inhibitors represent a rapidly expanding new 
class of anti-cancer therapy. Many TKIs have activity against c-KIT, a receptor tyrosine kinase 
which is essential for normal erythropoiesis and megakaryocyte function.
25
  Patients treated with 
TKIs that inhibit c-KIT, therefore, would be predicted to experience myelosuppression.
26
  In vivo 
c-KIT inhibition is also associated with hair depigmentation, which can be a useful biomarker for 
target inhibition (Figure 2).
27
  However, drugs such as pazopanib and sunitinib, which have in 
vitro and in vivo activity against c-KIT, are not reported as inducing myelosuppression in solid 
tumor patients.  In contrast, dasatinib and imatinib, which are reported to have in vitro activity 
against c-KIT, can readily induce myelosuppression in patients with Ph+ acute lymphocytic 
leukemia (Ph+ ALL) or chronic myeloid leukemia (CML).
28,29
  In patients with 
relapsed/refractory FLT3/ITD AML, treatment with the novel FLT3 inhibitor quizartinib was 
associated with myelosuppression, whereas in a similar patient population, a different FLT3 
inhibitor, sorafenib, induced no myelosuppression.
6,30
  To better understand the relationship 
between inhibition of c-KIT, FLT3, and marrow suppression, we studied a series of different 
TKIs using normal bone marrow progenitor assays and dose-response experiments with activated, 
phosphorylated c-kit.  Our findings highlight the importance of determining a therapeutic index 
between the targeted receptor and c-KIT.  This is an important consideration in the development 






Figure 1. Diagram of the FLT3 receptor. The FLT3 receptor has five extracellular 
immunoglobulin domains followed by a transmembrane domain.  Its cytoplasmic domain 
includes a juxtamembrane domain (the location of the internal tandem duplication 
mutation) followed by a split kinase domain (the location of the D835 residue where 





Figure 2. TKI induced hair depigmentation.  An AML patient before treatment (left) and 
54 days after treatment (right) with the c-Kit/FLT3 inhibitor, PLX3397. (This compound is 
currently being studied in a phase 1 trial- see NCT01349049;  pharmacokinetic data are not yet 
















Crenolanib has activity against FLT3/ITD AML cells 
Crenolanib (Figure 3A) was originally developed as an inhibitor of PDGFRB.  In 
a commercially-available assay of kinase selectivity (KinomeScan, DiscoveRx, San 
Diego, CA), crenolanib was demonstrated to have a high degree of selectivity for FLT3 
relative to other kinases (Figure 3B).   We compared the FLT3 inhibitory activity of 
crenolanib with sorafenib and quizartinib using cell lines expressing mutant and wild type 
FLT3 (Figure 4).  In immunoblot assays examining FLT3 autophosphorylation and 
phosphorylation of downstream signaling proteins (Figure 4A-B), crenolanib inhibited 
autophosphorylation of both wild type and ITD-mutated FLT3 to a similar degree, with 
an IC50 of approximately 2 nM.  In MTT assays, crenolanib exhibited a cytotoxic effect 
against Molm14 and MV4-11 cells in culture medium to a similar degree as sorafenib and 
somewhat less so compared with quizartinib (Figure 4C).  This effect was also observed 
in assays of apoptosis using Annexin V (Figure 4D).  Likewise, crenolanib inhibited 
FLT3 autophosphorylation in primary FLT3/ITD AML blasts (from a patient with a 
FLT3/ITD mutation at an allelic ratio of 0.95) in culture with an IC50 of 2.4 nM (Figure 
4E). 
Crenolanib has activity against FLT3/D835 point mutants 
Point mutations at residue D835 can arise in the wild type FLT3 receptor or 
within the context of an existing ITD mutation (i.e., within the same allele).  In order to 
test the inhibitory activity of crenolanib against both categories of D835 mutations, we 
generated a series of transfectants of the murine lymphoid cell line Ba/F3.  As shown in 




lacking any kinase domain mutation.  However, crenolanib was significantly more potent 
than quizartinib against the D835Y, D835F, and D835V mutant receptors.  Interestingly, 
crenolanib and quizartinib were of equal potency against the D835H and D835N variants.  
Crenolanib has minimal activity against the F691L variant. 
We next tested crenolanib against a series of primary AML samples with D835 
mutations arising both spontaneously and in the context of FLT3 inhibitor therapy.  
Figure 5A shows a dose response experiment using 3 primary AML samples in vitro, 
each of which harbored a D835 mutation (in a wild type FLT3 background, no ITD 
mutation).  Patients 2 and 3 harbored D835Y mutations and were newly-diagnosed, while 
patient 4, harboring a D835V mutation, was collected at relapse.  Crenolanib inhibited 
FLT3 autophosphorylation in all three samples, with IC50’s of 1.2, 8.1, and 2.0 nM, 
respectively.  No significant cytotoxicity was induced by the drug in the two diagnostic 
specimens, while the relapsed specimen did appear to respond (Figure 5B).  This is 
similar to what has been observed with FLT3/ITD-mutated samples, in that newly-
diagnosed cases are not generally responsive to highly selective FLT3 inhibition, while in 
the relapsed setting the response is more predictable.
31
  Examining this relapsed patient 
sample further, Figure 5C shows that crenolanib is more effective than either sorafenib or 
quizartinib at inhibiting FLT3 autophosphorylation and at inducing cytotoxicity.  Finally, 
the utility of crenolanib against a tyrosine kinase domain mutation in the background of a 
FLT3/ITD mutation is demonstrated in Figure 5D.  A FLT3/ITD AML patient (with an 
allelic ratio of 2.65) who was being maintained on sorafenib developed clinical 
progression, and was found to harbor a D835F mutation which was not present at the start 




effect against these blasts in vitro (there were insufficient blasts from this sample to 
perform immunoblotting). 
c-Kit inhibition and effects on hematopoietic colony formation 
FLT3 inhibitors often have inhibitory activity against the closely-related RTK, c-
KIT.  This may account to some degree for the myelosuppression, particularly the anemia 
and thrombocytopenia that is often observed in patients receiving FLT3 inhibitors in 
clinical trials.  An extensive literature supports the notion that suppression of c-KIT 
activity would be expected to result in impaired red cell and platelet production.
25
  A 
relative therapeutic index, therefore, would be expected to exist for inhibitors of class III 
RTKs such as crenolanib and quizartinib.  We compared the activity of both drugs 
against c-KIT using immunoblot assays with the erythroleukemia cell line, TF-1, which 
expresses wild type c-KIT (Figure 6A).  Quizartinib was the more potent inhibitor of c-
KIT in this assay.  In hematopoietic progenitor cell assays of normal donor marrow, 
quizartinib, but not crenolanib, was generally more suppressive of erythroid activity at 
concentrations consistent with those associated with c-KIT inhibition (Figure 6B).  
Crenolanib, therefore, has an advantage over quizartinib in this respect, in that the 












Figure 3B. KinomeScan results for crenolanib.  Shown are the results of all kinases in 





Figure 4A.  Activity of crenolanib against wild type and ITD-mutated FLT3 in vitro.  
FLT3/ITD cell lines (Molm14 and MV411) and FLT3 WT cell lines (SEMK2) were 
treated with crenolanib for one hour, then cells were lysed, immunoprecipitated for FLT3 





Figure 4B.  Activity of crenolanib against wild type and ITD-mutated FLT3 in vitro.  
An aliquot of the lysate of Molm14s treated with crenolanib from panel A was reserved 
for analysis of downstream signaling molecules including pAKT, pMAPK, pSTAT5, as 





Figure 4C.  Activity of crenolanib against wild type and ITD-mutated FLT3 in vitro.  
Cytotoxicity of these doses of crenolanib in FLT3/ITD cell lines was analyzed by MTT 





Figure 4D.  Activity of crenolanib against wild type and ITD-mutated FLT3 in vitro.  
Apoptosis induced by crenolanib and sorafenib 48 hrs after treatment of Molm14 cells 





Figure 4E.  Activity of crenolanib against wild type and ITD-mutated FLT3 in vitro.  
Patient blasts containing a FLT3/ITD mutation were treated with crenolanib, lysed, and 





Table 1.  Inhibitory activity of crenolanib against different FLT3 TKD mutations.  
Ba/F3 cell lines were treated with quizartinib or crenolanib for one hour, then cells were 
lysed, immunoprecipitated for FLT3 and analyzed by immunoblotting for phospho- and 
total FLT3.  Densitometry analysis was performed using Quantity One software (version 







Figure 5A.  Inhibitory activity of crenolanib against FLT3 TKD mutations in 
primary AML samples.  Blasts from patient 2 (de novo D835Y), patient 3 (de novo 
D835Y), and patient 4 (relapsed D835V) were incubated for one hour with crenolanib, 






Figure 5B.  Inhibitory activity of crenolanib against FLT3 TKD mutations in 
primary AML samples.  Blasts from the same patients in Figure 5A were treated with 





Figure 5C.  Inhibitory activity of crenolanib against FLT3 TKD mutations in 
primary AML samples.  Blasts from patient 4 were also treated with quizartinib and 
sorafenib in this analysis.  In a separate immunoblot experiment (inset), blasts from 
patient 4 were treated with 20 nM of quizartinib, crenolanib, and sorafenib for one hour, 






Figure 5D.  Inhibitory activity of crenolanib against FLT3 TKD mutations in 
primary AML samples.  Patient 5 had a FLT3/ITD mutation and was treated with 
sorafenib, responded, and then relapsed.  Blasts collected after relapse harbored a D835F 
mutation, along with the original FLT3/ITD mutation.  These blasts were treated with 
crenolanib, quizartinib, or sorafenib in 96 well plates for 72 hours and cytotoxicity was 





Figure 6A.  Inhibition of c-KIT and erythropoiesis.  TF-1 cells, which express WT c-
Kit, were treated with crenolanib or quizartinib for one hour.  In the last five minutes of 
drug treatment, 20 ng of SCF was added.  The cells were lysed, immunoprecipitated for 





Figure 6B.  Inhibition of c-KIT and erythropoiesis.  Normal human donor bone 
marrow (n=3) was collected and diluted to a concentration of 100,000 cells per mL in 
MethoCult.  Various concentrations of crenolanib or quizartinib were added and cells 
were plated in quadruplicate in 35 mm dishes.  Each dish was view under a light 














Crenolanib achieves inhibitory activity against FLT3/ITD and FLT3/D835 AML in 
vivo 
Crenolanib is currently being studied in a phase II clinical trial for patients with 
relapsed/refractory AML with FLT3 activating mutations (NCT01657682).  Patients are 
treated with 100 mg crenolanib orally every eight hours.  However, on study day 1, 
patients were given a single dose of drug so that single-dose pK studies could be 
conducted.  We used plasma samples collected from patients on day 1 of treatment with 
crenolanib for analysis of in vivo FLT3 inhibition using the PIA assay, and pK analysis 
was carried out using serum from these time points to determine serum drug 
concentrations at the corresponding PIA time points (Figures 7A-B).  No significant 
difference was seen between experiments performed in plasma compared to serum which 
showed IC50s against phospho-FLT3 of 48 nM and 40 nM, respectively.  Comparing the 
PIA results with the pK results, we observed that FLT3 inhibition was readily achieved 
throughout the dosing period.  A trough serum concentration of 100-200 nM appears to 
be required to maintain inhibition of FLT3 autophosphorylation to 10-15% of baseline.  
This PIA assay was performed using Molm14 cells, which harbor a FLT3/ITD mutation.  
To provide evidence for the in vivo activity of crenolanib against kinase domain 
mutations, we took blasts from patient 4 (described above), which contained a D835V 
mutation, and used them in a PIA assay of trough plasma samples from several different 
trial patients.  As shown in Figure 7C, steady state (Day 15) levels of crenolanib were 
quite sufficient to profoundly inhibit this mutant FLT3 receptor.  These clinical 
correlative data indicate that AML patients treated with 100 mg crenolanib every eight 




target, whether it is a FLT3/ITD mutation or a FLT3/D835 mutation.  Data regarding the 
safety, tolerability, and efficacy of crenolanib in these patients is not yet available, as 







Figure 7A.  Crenolanib inhibits FLT3 in vivo.  Plasma samples from patient 6 and 
patient 7 were collected as part of the phase II clinical trial of crenolanib.  Patients 
received a single dose of drug on Day 1, and samples were collected for PIA and pK 
analysis.  Molm14 cells were incubated with each plasma sample for one hour, lysed, 






Figure 7B.  Crenolanib inhibits FLT3 in vivo.  The same time course samples from 
these patients, shown in 7A, were analyzed by mass spectroscopy for serum drug 





Figure 7C.  Crenolanib inhibits FLT3 in vivo.  Blasts from patient 4 (relapsed D835V) 
were utilized for a PIA assay with steady state plasma samples from five different 
patients enrolled on the crenolanib trial.  Blasts were incubated in plasma for one hour, 
lysed, immunoprecipitated for FLT3, and analyzed by immunoblot for phospho- and total 
FLT3.  Densitometry was performed on this blot and results are described under %FLT3 















The FLT3 receptor is expressed in a limited number of tissues, mainly 
hematopoietic progenitor cells.  However, its corresponding ligand, FL is expressed 
ubiquitously.  Binding of FL to FLT3 induces dimerization of the receptor, 
autophosphorylation, and subsequent phosphorylation of downstream signaling 
molecules.  Structural studies of ITDs in the juxtamembrane domain have shown that 
these mutations induce constitutive activation and ligand independent phosphorylation of 
the receptor.
32
  More recently, it has been shown that in FL knockout systems, the 
FLT3/ITD receptor shows only modest phosphorylation, but full phosphorylation when 
FL was re-introduced.
33
  This demonstrates that FL still plays an important role in 
FLT3/ITD signaling despite the constitutive activation of the receptor.  FL may play a 
role in a clinical setting where chemotherapy induces a dramatic rise in plasma FL 
levels.
34
  The presence of FL has also been shown to reduce the efficacy of some FLT3 
TKIs.
34
  The tumor microenvironment has been shown to play a major role in many 
cancer types including AML
35,36
  and FL is expressed on the cell surface of bone marrow 
stromal cells which could reduce the efficacy of TKIs against AML blasts residing in the 
bone marrow.  These observations demonstrate that effect of FL should be taken into 
account when developing new therapies.  We hypothesized that monoclonal antibodies 
targeting FL would lessen the impact of stromal-mediated resistance to TKIs associated 
with stromal cell surface FL. 
In Figure 8, blasts from two patients were treated with a FLT3 inhibitor in 
suspension culture and co-cultured with primary human bone marrow stroma.  This 
experiment is designed to predict the effect of a FLT3 TKI on peripheral blood blasts, 




the bone marrow niche, demonstrated by the bone marrow stroma co-culture system.  
Quantification of this effect is displayed in Table 2.  The stromal co-culture system 
causes a 4-6 fold shift in the IC50 of crenolanib.  This experiment reveals that the dose 
selected to treat a patient with a FLT3 TKI must be significantly higher to affect the 
blasts residing in the protective bone marrow niche than to simply eliminate circulating 
blasts.   
To address this issue, we proposed targeting the bone marrow stromal cells to 
overcome their protective effect.  We used novel anti-FL monoclonal antibodies 
produced by Symphogen (Lyngby, Denmark) with the aim of neutralizing receptor ligand 
binding and optimizing efficacy of FLT3 TKIs.  Anti-FL mAbs 9449 and 9373 have no 
effect on WT FLT3 or FLT3/ITD phosphorylation and do not induce cytotoxicity in cell 
lines in suspension (Figure 9A and 9B).  This shows that targeting FL alone has no effect 
on AML cells themselves.  To test the effect of these mAbs in the context of the bone 
marrow microenvironment, primary blasts were incubated in parallel in suspension 
culture and stromal cell co-culture, with crenolanib, with or without the addition of mAb 
9449 and analyzed by immunoblot (Figure 10). The addition of mAb 9449 is able to 
reduce the stromal shift of crenolanib IC50 from 1.96 to 1.16 fold (Table 3). This 
highlights the potential for targeting FL to overcome stromal-mediated resistance to 






Figure 8. Stromal co-culture causes increased FLT3 phosphorylation.  Blasts from 
patient 1 and patient 4 were treated with a dose response of crenolanib in two parallel 
conditions: in suspension culture or co-cultured with primary bone marrow stroma.  
Blasts were incubated with crenolanib in medium for one hour, lysed, 






Table 2. Stromal co-culture causes a shift in IC50 of FLT3 TKIs.  This table is a 
quantification of the immunoblots shown in Figure 8.  Densitometry analysis was 
performed using Quantity One software (version 4.5.0).  IC50s were calculated by 







Figure 9A.  Anti FL mAb effect on WT FLT3 and FLT3/ITD cell lines.  Molm14 and 
SEMK2 cells were incubated with 100µg/mL of anti-FL mAb 9373, 9449, for two hours 
or 100nM quizartinib for one hour in medium, lysed, immunoprecipitated for FLT3, and 





Figure 9B.  Anti FL mAb effect on WT FLT3 and FLT3/ITD cell lines.  Molm14 
cells were treated with 100µg/mL of anti-FL mAb 9373, anti-FL mAb 9449, anti-FL 
mAb 9373 and 9449, or sorafenib in 96 well plates for 48 hours and cytotoxicity was 







Figure 10. Stromal co-culture induced shift in TKI IC50 is reduced by anti-FL 
mAbs.  Primary patient blasts (patient 4) were treated with crenolanib for one hour in 
four parallel conditions.  In the upper blot, blasts were incubated in suspension with 
crenolanib and co-cultured with stroma with crenolanib.  In the lower blot, blasts were 
incubated in suspension with crenolanib and mAb9449 and co-cultured with stoma with 
crenolanib and mAb9449.  Following one hour of drug treatment, cells were lysed, 







Table 3. Stromal co-culture induced shift in TKI IC50 is reduced by anti-FL mAbs. 
Primary patient blasts were treated with crenolanib or crenolanib and mAb9449 in 
suspension or co-cultured with stroma for one hour, then cells were lysed, 
immunoprecipitated for FLT3 and analyzed by immunoblotting for phospho- and total 
FLT3 as shown in Figure 10.  Densitometry analysis was performed using Quantity One 
software (version 4.5.0).  IC50s were calculated by regression analysis after linear 

















Inhibition of c-Kit disrupts hematopoietic progenitor activity 
Dasatinib is a multi-targeted kinase inhibitor with activity against Bcr-Abl, SRC, and c-
Kit, among others.  Using TF-1 cells stimulated with stem cell factor (SCF), we estimated that the 
concentration of dasatinib necessary to inhibit 50% of baseline c-KIT activity (IC50) in an 
immunoblot assay is 1.5 nM in culture medium and 30 nM in 100% human plasma (Figure 11A).  
It has a relatively short half-life of 3-5 hours, and patients achieve maximum plasma 
concentrations of around 84 nM.
37
  In colony formation assays with normal human bone marrow, 
dasatinib had a mild effect on the formation of myeloid and considerably inhibited the formation 
of erythroid colonies (Figure 11B).  Dasatinib has been reported to cause myelosuppression in 
leukemia patients,
28
 as well as hair depigmentation.
38
  Pazopanib is reported to be a potent 
inhibitor of VEGFR, PDGFR, and c-Kit.
39
  We found it to have an IC50 against c-Kit in culture 
medium of 3.7 nM.  While pazopanib has a seemingly high IC50 in human plasma of 36 µM due 
to high plasma protein binding (Figure 11A), many patients are able to achieve trough drug levels 
of 50 µM.
39
  In colony formation assays with normal human bone marrow, pazopanib caused 
substantial inhibition of erythroid colony formation and only moderate inhibition of myeloid 
colonies (Figure 11B).  Hair depigmentation is listed as a common adverse event in the FDA 
label for pazopanib, indicative of in vivo c-Kit inhibition.  While both dasatinib and pazopanib 
are potent in vitro inhibitors of c-Kit and both inhibit erythroid colony formation in vitro (and 
cause hair depigmentation), of the two drugs, only dasatinib has been reported to cause 
myelosuppression in vivo.
28,39
  indicating that, at least in the case of pazopanib, the progenitor cell 
assay does not fully replicate conditions in vivo.  Pazopanib is used as a treatment for patients 
with solid tumors and is not used to treat hematological malignancies.  One explanation for this 
result is that c-Kit inhibition may not induce clinically significant myelosuppression in the setting 





FLT3 inhibition has no effect on hematopoietic progenitor activity 
FLT3 and c-KIT are structurally related RTKs that both play important roles in early 
hematopoiesis.
40
  In contrast to c-Kit, knockout of FLT3 is not embryonic lethal in murine 
transgenic models.  Given their somewhat redundant signaling properties, there has been concern 
that simultaneous inhibition of FLT3 and c-KIT could result in more profound myelosuppression 
compared to inhibition of c-Kit alone.  Sorafenib is a potent FLT3 TKI (IC50 in culture medium 3-
5 nM) that has demonstrated efficacy in the treatment of relapsed/refractory FLT3/ITD AML 
patients.
6
  There is no reported inhibition of c-Kit by sorafenib, nor have there been any reports of 
myelosuppression or hair depigmentation in clinical studies of this agent.  These observations are 
consistent with the results of our immunoblot assays of c-Kit inhibition (Figure 11A) and by 
colony formation assays in which sorafenib showed no significant inhibition progenitor cell 
activity (Figure 11B).  Quizartinib is a novel, potent FLT3 inhibitor (IC50 in culture medium 2 
nM; in plasma 18 nM) with a long half-life (1.5 days), and AML patients readily achieve 
micromolar plasma concentrations of quizartinib.
8
  Quizartinib is a modestly potent c-Kit 
inhibitor with an IC50 in culture medium of 28 nM and myelosuppression was observed in clinical 
trials of quizartinib.
30
  In colony formation assays, quizartinib inhibited both myeloid and 
erythroid colony formation, consistent with what we observed with dasatinib and pazopanib 
(Figure 11B).  Quizartinib-induced myelosuppression, therefore, is probably mediated through 
inhibition of c-Kit. 
It is still formally possible that while FLT3 inhibition by itself has no effect on 
hematopoiesis, it could contribute to c-Kit-induced marrow suppression.  Exogenous FLT3 ligand 
(FL) is known to shift the dose response to FLT3 inhibitors upward.{Sato, 2011 #1013}  If FLT3 
inhibition were contributing to the suppression of colony formation induced by quizartinib, then 
the addition of FL to the methylcellulose medium would be predicted to blunt the inhibitory 




formation with 200 nM quizartinib with or without exogenous FL (10 ng/mL) (data not shown), 
suggesting that FLT3 inhibition does not contribute to marrow suppression from quizartinib. In 
summary, our findings show that the more potent c-Kit inhibitors induce greater inhibition of 
erythroid colony formation and FLT3 inhibition alone appears to have minimal if any 
contribution to erythroid colony suppression without concomitant c-Kit inhibition.   
Defining a therapeutic index 
Table 4 lists several TKIs that we characterized according to their activity against both 
FLT3 and c-Kit receptors in culture medium and 100% human plasma.  Each TKI was ranked 
according to our estimate of its relative potency against c-Kit in vivo, based on pharmacokinetic 
data, in vitro potency, the frequency of the clinical biomarker of hair depigmentation, and the 
frequency of myelosuppression observed in patients.  Table 4 demonstrates a pattern of 
characteristics of TKIs that could be used to predict in vivo c-Kit inhibition.  However, some 
TKIs do not strictly follow this pattern, such as pazopanib, which causes in vitro c-Kit inhibition 
and in vivo hair depigmentation but not myelosuppression in patients.  This could be attributed to 
these TKIs having a variable range of activity against many kinases so it may be difficult to credit 
any one kinase alone with a given side effect.
7
  Clinicians treating patients with hematologic 
malignancies with c-Kit inhibitors must be aware of this therapeutic index in order to minimize 






Figure 11A. c-Kit inhibition correlates with myelosuppression in vitro.  TF-1 cells were 
treated with drug for 1 hour (20 ng SCF was added in the last five minutes of incubation) in cell 





Figure 11B. c-Kit inhibition correlates with myelosuppression in vitro.  Normal human bone 
marrow (n=3) was collected and mononuclear cells were isolated.  Mononuclear cells were plated 
in 35 mm dishes at a concentration 100,000 cells per mL in MethoCult containing various 
concentrations of a TKI in quadruplicate.  Plates were analyzed 10-14 days later by morphology 


































26 nM Yes Yes 
41-86 
hours 
P: 135 nM 
T: 82 nM 
41
 
Pazopanib >2 µM 3.7 nM N/A 36 µM Yes No 
31 
hours 
P: 95 µM 
T: 50 µM 
39
 










1.5 nM N/A 30 nM Occasional Yes 
3-5 
hours 




Imatinib >2 µM 122 nM N/A 5.4 µM Occasional Yes 
19 
hours 
P: 4.7 µM 
T: 1.9 µM 
42
 
Crenolanib 2.6 nM 62 nM 48 nM 2.0 µM No No 
12 
hours 












P: 12.9 µM 





Table 4. Ranking of a panel of TKIs based on predicted potency against c-Kit in 
vivo.  For FLT3 data, MOLM14 cells were incubated with drug for 1 hour, lysed, 
immunoprecipitated for FLT3, and immunoblotted for phospho- and total FLT3.  For c-
Kit data, TF-1 cells were incubated with drug for 1hr with 20 ng SCF (PeproTech, Rocky 
Hill NJ) added to each sample in the last 5 minutes of drug incubation.  The treated TF-1 
cells were lysed, immunoprecipitated for c-Kit, and immunoblotted for phospho- and 
total c-Kit.  Densitometry analysis was performed using Quantity One software (version 


















FLT3 inhibitors have been under investigation for over a decade.  First generation 
inhibitors, such as lestaurtinib, midostaurin, and sunitinib, were re-purposed multi-
targeted compounds with minimal clinical activity as single agents because they lacked 
potency and/or tolerability.  Second generation inhibitors such as quizartinib and 
PLX3397 are more selective, and therefore presumably better tolerated at concentrations 
necessary to fully inhibit FLT3 in vivo.  This has led to more impressive clinical results, 
particularly with quizartinib,
8,45
 but has also not unexpectedly led to the emergence of 
resistance-conferring point mutations, most commonly at residue D835.  The emergence 
of these mutations in the context of FLT3 inhibition represents evidence that FLT3 
mutations- either the ITD mutation at diagnosis or the ITD/D835 combination- represent 
driver mutations for this disease.  Furthermore, while isolated FLT3/D835 mutations (i.e., 
those occurring in the absence of a FLT3/ITD mutation) overall have an uncertain 
prognostic impact, in some cases they probably also function as driver mutations (e.g., 
see Figure 3), and therefore warrant targeting.
46
  
Crenolanib has been studied in patients with solid tumors,
19
 and is currently being 
studied in patients with PDGFR-driven gastrointestinal stromal tumors (NCT01243346) 
and in pediatric patients with gliomas (NCT01393912), as well as in AML patients with 
FLT3 activating mutations (NCT01522469; NCT01657682).  Preliminary clinical and 
pharmacokinetic data from these studies indicate that the drug is cytochrome P450-
metabolized, has an approximate terminal half-life (t1/2) of 8 hours, and is well-tolerated 
at 100 mg three times daily (Arog Pharmaceuticals, personal communication).  This t1/2 is 
considerably shorter than that of sorafenib (~24 hours) or quizartinib (1.5 days),
8,47
 




Crenolanib has no activity against the F691 point mutations, which also emerged 
during quizartinib, albeit at a lower frequency than the D835 mutations, and we did not 
test the drug exhaustively against all of the other relatively uncommon FLT3 point 
mutations that have been previously reported.
18,46,48-50
  It is likely that as this field 
progresses, a number of compounds will emerge that have overlapping activity against 
FLT3 variants,
51,52
 similar to the case with inhibitors of BCR-ABL.  However, FLT3/ITD 
and FLT3/D835 mutations, either arising spontaneously or in response to treatment with 
a FLT3TKI, constitute the vast bulk of clinically important FLT3 activating mutations, 
and we have demonstrated here that crenolanib not only has in vitro activity against them, 
oral dosing of the drug can achieve inhibitory concentrations against these mutations in 
AML patients. 
Myelosuppression can be a challenging clinical parameter to evaluate in any trial 
involving AML patients.  Most AML patients enrolled on early phase studies are already 
myelosuppressed from their disease burden.  Nonetheless, suppression of bone marrow 
function to some degree is almost always a feature of TKIs that have activity against c-
KIT, and the relatively limited activity of crenolanib against c-KIT may offer a unique 
advantage of this drug over others in this class. 
In summary, our results indicate that crenolanib represents the next generation of 
FLT3 TKIs, one with a broader range of activity than the other agents in development.  
Phase 2 trials of this drug in FLT3-mutated AML patients are ongoing (NCT01657682 
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